Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heidi Roschitzki-Voser

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Molecular Biology|September 5, 2009
The crystal structure of human pyrin b30.2 domain: implications for mutations associated with familial Mediterranean feverChristopher Weinert, Christian Grütter, Heidi Roschitzki-Voser, et al.
Journal of Cell Science|August 16, 2015
Altering lamina assembly reveals lamina-dependent and -independent functions for A-type laminsMonika Zwerger, Heidi Roschitzki-Voser, Reto Zbinden, et al.
Protein Science : a Publication of the Protein Society|July 23, 2013
Design, construction, and characterization of a second-generation DARP in library with reduced hydrophobicityMarkus A Seeger, Reto Zbinden, Andreas Flütsch, et al.
Protein Expression and Purification|June 12, 2012
Human caspases in vitro: expression, purification and kinetic characterizationHeidi Roschitzki-Voser, Thilo Schroeder, Esther D Lenherr, et al.
Chemistry & Biology|September 21, 2010
Selective and sensitive monitoring of caspase-1 activity by a novel bioluminescent activity-based probeMaik Kindermann, Heidi Roschitzki-Voser, Dejan Caglic, et al.
Structure (London, England : 1993)|May 16, 2007
Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanismAndreas Schweizer, Heidi Roschitzki-Voser, Patrick Amstutz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2020
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)Solange Peters, Enriqueta Felip, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Sarah Danson, Dunson Ejedepang, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Molecular Biology|September 5, 2009
The crystal structure of human pyrin b30.2 domain: implications for mutations associated with familial Mediterranean feverChristopher Weinert, Christian Grütter, Heidi Roschitzki-Voser, et al.
Journal of Cell Science|August 16, 2015
Altering lamina assembly reveals lamina-dependent and -independent functions for A-type laminsMonika Zwerger, Heidi Roschitzki-Voser, Reto Zbinden, et al.
Protein Science : a Publication of the Protein Society|July 23, 2013
Design, construction, and characterization of a second-generation DARP in library with reduced hydrophobicityMarkus A Seeger, Reto Zbinden, Andreas Flütsch, et al.
Protein Expression and Purification|June 12, 2012
Human caspases in vitro: expression, purification and kinetic characterizationHeidi Roschitzki-Voser, Thilo Schroeder, Esther D Lenherr, et al.
Chemistry & Biology|September 21, 2010
Selective and sensitive monitoring of caspase-1 activity by a novel bioluminescent activity-based probeMaik Kindermann, Heidi Roschitzki-Voser, Dejan Caglic, et al.
Structure (London, England : 1993)|May 16, 2007
Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanismAndreas Schweizer, Heidi Roschitzki-Voser, Patrick Amstutz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 3, 2019
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trialGiuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2020
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14)Solange Peters, Enriqueta Felip, Urania Dafni, et al.
Lung Cancer (Amsterdam, Netherlands)|September 20, 2021
Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trialsSolange Peters, Sarah Danson, Dunson Ejedepang, et al.
Pageof 2